secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0001193125-24-047916
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian reports $645.7M cash, $237.7M net loss; VRDN-001 Phase 3 readouts mid-2024
--------------------------------------------------------------------------------

- Cash, cash equivalents and short-term investments ~$645.7M as of Jan 31, 2024 (preliminary), extending runway into H2 2026.
- Net loss for FY2023 was $237.7M vs $129.9M in 2022; R&D expenses rose to $159.8M.
- VRDN-001 Phase 3 THRIVE topline data expected mid-2024; THRIVE-2 at year-end 2024.
- VRDN-003 subcutaneous pivotal program expected to start mid-2024 pending regulatory alignment.
- FcRn inhibitor VRDN-006 IND submission anticipated by year-end 2024; VRDN-008 NHP data H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312524047916/0001193125-24-047916-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312524047916/d802648d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-047916

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer